Duration of Protection and Age-Dependence of the Effects of the SPf66 Malaria Vaccine in African Children Exposed to Intense Transmission of Plasmodium falciparum

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical episodes over a period of 18 months after the third dose is 25% (95% confidence interval [CI], 1%–44%; P = .044). The ob...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 174; no. 2; pp. 367 - 372
Main Authors:	Alonso, Pedro L., Smith, Tom A., Armstrong-Schellenberg, Joanna R. M., Kitua, Andrew Y., Masanja, Honorathi, Hayes, Richard, Hurt, Nicole, Font, Fidel, Menendez, Clara, Kilama, Wencislaus L., Tanner, Marcel
Format:	Journal Article
Language:	English
Published:	Chicago, IL The University of Chicago Press 01-08-1996 University of Chicago Press Oxford University Press
Subjects:	Age Factors Age groups Biological and medical sciences Child, Preschool Children Cross-Sectional Studies Dosage Epidemiology Experimentation Follow-Up Studies Human protozoal diseases Humans Incidence Infant Infectious diseases Major Articles Malaria Malaria vaccine Malaria Vaccines - therapeutic use Malaria, Falciparum - blood Malaria, Falciparum - epidemiology Malaria, Falciparum - prevention & control Malaria, Falciparum - transmission Medical sciences Parasites Parasitic diseases Placebos Plasmodium falciparum Population Surveillance Protozoal diseases Protozoan Proteins - therapeutic use Recombinant Proteins Tanzania - epidemiology Time Factors Tropical medicine Vaccination Vaccines, Synthetic - therapeutic use Africa Tanzania Human Protozoa Protozoal disease Malaria Treatment efficiency Vaccine Parasitosis Infection Immunoprophylaxis Plasmodium falciparum Immunogenicity Sporozoa Child Age
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!